HA+马利兰/HA方案初治慢性粒细胞白血病疗效观察  

HA Plus Myleran or HA Protocol Use for Initially Treated Chronic Myelogenous Leukemia

作　　者：陈为民[1] 杨瑞芬[1] 周明宣[1] 陈捷[1] 李良庆[1] 

机构地区：[1]南京军区福州总医院血液科,350001

出　　处：《临床血液学杂志》1996年第1期13-15,共3页Journal of Clinical Hematology

摘　　要：12例初诊的慢性粒细胞白血病(CML)接受HA+马利兰/HA方案化疗.三尖杉酯硷 2～3mg/d,阿糖胞苷100～200ng/d,7～10天为1疗程.7例在停HA后即连用马利兰4～8mg/d×5～8天.1疗程未达CR者间隔2～3周开始第2疗程直至CR.结果;1疗程CR率66.6%,有效率100%;2疗程CR率100%;达CR中位时间30天.其中2例ph_1;阳性率治疗前后对比下降平均为48.6%.提示:HA+马利兰/HA方案缓解率及有效率明显高于单一马利兰;显效快,达CR迅速,作用轻.HA+马利兰较HA能加速CML获CR.对慢性期CML细胞遗传学有较好改善.From 1992 to 1994, 12 Cases of initially diagnosed chronic myelogenous leukemia were treated with HA (Homoharring tonine and Ara-C) or HA plus myleran regimen. All cases were response and 8 cases (66. 6%) reached complete remission (CR) after first course. 12 cases (100%) achieved CR after two courses. From treatment beginning to CR, there were median duration of 30 days (range 20-58). Ph1-Positive rates were reduced to the mean of 48. 6% at two cases. No severe toxicity was found. It is suggested that HA plus myleran or HA protocol have effect on initially treated chronic myelogenous leukemia.

关 键 词：白血病 慢性粒细胞 HA方案 马利兰 药物疗法 

分 类 号：R733.72[医药卫生—肿瘤]